Study wrapper · #1051
Papular granuloma annulare associated with tirzepatide: A case report.
Howard T, Clichy-Silva A, Kerdel F JAAD case reports. 2026.
DOI: 10.1016/j.jdcr.2026.06.046PubMed: 42499401
Editor's note
A single-patient case report noting papular granuloma annulare occurring alongside tirzepatide use. Case reports document a possible association but cannot establish causation, and no abstract detail was available to assess the clinical context. It is a useful safety-signal note rather than evidence of a consistent effect.
Plain-language abstract
This single case report describes papular granuloma annulare, a benign skin condition, arising in a patient using tirzepatide. A case report cannot establish whether the medication was the cause.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Mixed
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillarsn=——2026